|
1
|
Thompson LD: Osteosarcoma. Ear Nose Throat
J. 92:288–290. 2013.PubMed/NCBI
|
|
2
|
Wu X, Zhong D, Gao Q, Zhai W, Ding Z and
Wu J: MicroRNA-34a inhibits human osteosarcoma proliferation by
downregulating ether à go-go 1 expression. Int J Med Sci.
10:676–682. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shin VY, Siu JM, Cheuk I, Ng EK and Kwong
A: Circulating cell-free miRNAs as biomarker for triple-negative
breast cancer. Br J Cancer. 112:1751–1759. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Munagala R, Aqil F, Vadhanam MV and Gupta
RC: MicroRNA ‘signature’ during estrogen-mediated mammary
carcinogenesis and its reversal by ellagic acid intervention.
Cancer Lett. 339:175–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Negrini M and Calin GA: Breast cancer
metastasis: A microRNA story. Breast Cancer Res. 10:2032008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Osaki M, Takeshita F, Sugimoto Y, Kosaka
N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T,
et al: MicroRNA-143 regulates human osteosarcoma metastasis by
regulating matrix metalloprotease-13 expression. Mol Ther.
19:1123–1130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang G, Nishimoto K, Zhou Z, Hughes D and
Kleinerman ES: miR-20a encoded by the miR-17-92 cluster increases
the metastatic potential of osteosarcoma cells by regulating Fas
expression. Cancer Res. 72:908–916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jin J, Cai L, Liu ZM and Zhou XS:
miRNA-218 inhibits osteosarcoma cell migration and invasion by
down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev.
14:3681–3684. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duan Z, Choy E, Harmon D, Liu X, Susa M,
Mankin H and Hornicek F: MicroRNA-199a-3p is downregulated in human
osteosarcoma and regulates cell proliferation and migration. Mol
Cancer Ther. 10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bassampour SA, Abdi R, Bahador R, Shakeri
M, Torkaman A, Yahaghi E and Taheriazam A: Downregulation of
miR-133b/miR-503 acts as efficient prognostic and diagnostic
factors in patients with osteosarcoma and these predictor
biomarkers are correlated with overall survival. Tumour Biol. Aug
16–2015.(Epub ahead of print). PubMed/NCBI
|
|
17
|
Chong Y, Zhang J, Guo X, Li G, Zhang S, Li
C, Jiao Z and Shao M: MicroRNA-503 acts as a tumor suppressor in
osteosarcoma by targeting L1CAM. PLoS One. 9:e1145852014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu B and Bi W: Role of microRNA-503 in the
suppression of osteosarcoma cell proliferation and migration via
modulation of fibroblast growth factor 2. Mol Med Rep.
12:7433–7438. 2015.PubMed/NCBI
|
|
19
|
Guo X, Zhang J, Pang J, He S, Li G, Chong
Y, Li C, Jiao Z, Zhang S and Shao M: MicroRNA-503 represses
epithelial-mesenchymal transition and inhibits metastasis of
osteosarcoma by targeting c-myb. Tumour Biol. 37:91881–9187. 2016.
View Article : Google Scholar
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen G, Fang T, Huang Z, Qi Y, Du S, Di T,
Lei Z, Zhang X and Yan W: MicroRNA-133a inhibits osteosarcoma cells
proliferation and invasion via targeting IGF-1R. Cell Physiol
Biochem. 38:598–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peng Y, Liu YM, Li LC, Wang LL and Wu XL:
microRNA-503 inhibits gastric cancer cell growth and
epithelial-to-mesenchymal transition. Oncol Lett. 7:1233–1238.
2014.PubMed/NCBI
|
|
23
|
Liu L, Qu W and Zhong Z: Down-regulation
of miR-503 expression predicate advanced mythological features and
poor prognosis in patients with NSCLC. Int J Clin Exp Pathol.
8:5609–5613. 2015.PubMed/NCBI
|
|
24
|
Xiao F, Zhang W, Chen L, Xie H, Xing C, Yu
X, Ding S, Chen K, Guo H, Cheng J, et al: MicroRNA-503 inhibits the
G1/S transition by downregulating cyclin D3 and E2F3 in
hepatocellular carcinoma. J Transl Med. 11:1952013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang SW, Yue J, Wang BC and Zhang XL:
miR-503 inhibits cell proliferation and induces apoptosis in
colorectal cancer cells by targeting E2F3. Int J Clin Exp Pathol.
8:12853–12860. 2015.PubMed/NCBI
|
|
26
|
Ide S, Toiyama Y, Shimura T, Kawamura M,
Yasuda H, Saigusa S, Ohi M, Tanaka K, Mohri Y and Kusunoki M:
MicroRNA-503 promotes tumor progression and acts as a novel
biomarker for prognosis in oesophageal cancer. Anticancer Res.
35:1447–1451. 2015.PubMed/NCBI
|
|
27
|
King H, Aleksic T, Haluska P and Macaulay
VM: Can we unlock the potential of IGF-1R inhibition in cancer
therapy? Cancer Treat Rev. 40:1096–1105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kolb EA, Kamara D, Zhang W, Lin J,
Hingorani P, Baker L, Houghton P and Gorlick R: R1507, a fully
human monoclonal antibody targeting IGF-1R, is effective alone and
in combination with rapamycin in inhibiting growth of osteosarcoma
xenografts. Pediatr Blood Cancer. 55:67–75. 2010.PubMed/NCBI
|
|
29
|
Maniscalco L, Iussich S, Morello E,
Martano M, Gattino F, Miretti S, Biolatti B, Accornero P,
Martignani E, Sánchez-Céspedes R, et al: Increased expression of
insulin-like growth factor-1 receptor is correlated with worse
survival in canine appendicular osteosarcoma. Vet J. 205:272–280.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang J, Li B, Yuan L and Ye Z: Prognostic
value of IGF-1R expression in bone and soft tissue sarcomas: A
meta-analysis. Onco Targets Ther. 8:1949–1955. 2015.PubMed/NCBI
|
